novo nordisk's semaglutide asks FDA to prevent compounders from making GLP-1 knockoffs Novo Nordisk's semaglutide shows promise

For ulcerative colitis patients, this genetic context may help provide a more complete picture of how your body regulates appetite, glucose metabolism, and GLP-1 receptor signalingsupporting a more informed discussion with your gastroenterologist

Genetic analysis implicates a molecular chaperone complex in regulating epigenetic Silencing of methylated genomic regions

Oral birth control pills may not work as well if you take Zepbound

Finding it difficult to lose weight became ....

Avoid using the same spot repeatedly to minimize irritation

Based on this evidence, and the results generated in the present study, once-weekly semaglutide would likely represent an effective treatment while providing value for money if used as second-line therapy in the general population with type 2 diabetes in the UK